Video Experimental Relacionado
Updated: Nov 19, 2025
12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
35.1K
Tratamientos dirigidos a las vías IL-23 e IL-17 en la psoriasis
Kamran Ghoreschi1, Anna Balato2, Charlotta Enerbäck3
1Department of Dermatology, Venereology, and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany; Charité-Universitätsmedizin Berlin, Berlin, Germany.
Lancet (London, England)
|January 30, 2021
Resumen
La psoriasis, una enfermedad inflamatoria crónica de la piel, se trata eficazmente mediante el bloqueo de las vías IL-23 e IL-17. Las nuevas terapias dirigidas a esta vía son prometedoras para el manejo de la psoriasis y afecciones relacionadas.
Área de la Ciencia:
- Inmunología
- Dermatología
- Medicina traslacional
Sus antecedentes:
- La psoriasis es una enfermedad inflamatoria crónica de la piel que afecta al 2-3% de la población mundial, caracterizada por lesiones cutáneas y efectos sistémicos.
- La enfermedad implica problemas de hiperproliferación y diferenciación de queratinocitos, impulsados por los mediadores inmunes de las vías IL-23 e IL-17.
Objetivo del estudio:
- Revisar los avances en la comprensión y tratamiento de la psoriasis a través de la inmunología traslacional.
- Destacar la eficacia de la orientación de la vía IL-23/IL-17 en el tratamiento de la psoriasis.
Principales métodos:
- Revisión de la literatura actual sobre la patogénesis y el tratamiento de la psoriasis.
- Análisis de terapias aprobadas y en investigación dirigidas a las vías IL-23 e IL-17.
Principales resultados:
- La orientación de la vía IL-23/IL-17 ha dado lugar a tratamientos exitosos para la psoriasis, con eficacia clínica significativa.
- Los biológicos aprobados dirigidos a IL-23, IL-17 y IL-17RA demuestran excelentes resultados.
- Los inhibidores de la vía intracelular (por ejemplo, TYK2, RORγt) están en desarrollo clínico.
Conclusiones:
- La vía IL-23/IL-17 es un objetivo validado para el tratamiento de la psoriasis, con un éxito terapéutico significativo.
- Aunque es eficaz para los síntomas de la piel y la artritis psoriásica, la modificación de la enfermedad a largo plazo y los efectos de comorbilidad requieren más investigación.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:24T Cell Types and Functions
1.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
295
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
295
01:20The JAK-STAT Signaling Pathway
10.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.3K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
300
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
300
01:22iPS Cell Differentiation
2.9K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
306
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
306